Reports & White Papers

View the latest Biosimilars Council reports and white papers for detailed information about what biosimilars are, how they work and how they generate savings for patients and the health care system.

2022 U.S. Generic and Biosimilar Savings Report: Biosimilars Deliver on Their Promise

The 2022 U.S. Generic and Biosimilar Savings Report, the annual report from the Association for Accessible Medicines and its Biosimilars... Read more »

2021 U.S. Generic and Biosimilar Medicines Savings Report: The Promise of Biosimilars

The 2021 U.S. Generic and Biosimilar Medicines Savings Report, featuring data from IQVIA, proves that the promise of biosimilars is... Read more »

AAM Report: Securing Sustainable Markets

The first in a series of papers, this paper examines the challenges to market sustainability for generic and biosimilar medicines... Read more »
twitter chat

Global Roadmap for Tailored Clinical Biosimilar Development: Instrumental for Sustainable Access to Biologics

Following its first peer-reviewed scientific paper on biosimilar medicines development: the Path Towards Tailored Clinical Biosimilar Development (BioDrugs), the International... Read more »
biosimilars in the pharmacy

Biosimilars In The Pharmacy

Biosimilars in the pharmacy benefit employers driving appropriate use and transparency. Despite the fact that less than 2 percent of... Read more »
europe's biosimilars market

Lessons for the United States on Europe’s Biosimilar Experience

Alex Brill, Founder of Matrix Global Advisors (MGA), an economic consulting firm, and a Resident Fellow at AEI, details misconceptions... Read more »
barriers to biosimilar adoption

Biosimilars Uptake Failure

America’s health care system is eager for biosimilars, especially in light of mounting evidence that they deliver increased patient access... Read more »

Patent Abuse Blocks Access to Biosimilars for Patients

As prescription drug costs continue to increase, biosimilar medicines represent hope for patients seeking access to more affordable treatment. Biosimilars... Read more »

Insulin Biosimilars: Ensuring Access for America’s Diabetes Patients

Insulin has been available to America’s diabetes patients for decades. Millions rely on this medicine every day to control their... Read more »
The Biosimilars Council - 2018 Access and Savings Report Cover Zoomed In

2018 Generic Drug Access & Savings in the U.S.

This annual report is produced by the IQVIA, the standard-bearer for measuring data, pharmaceutical use and spending in the United... Read more »
The Biosimilars Council - Breaking Through on Biosimilars Whitepaper

White Paper: Breaking Through on Biosimilars

America’s patients who suffer from many complex and chronic diseases have promising new treatment options in biologic and specialty medicines.... Read more »
Patient Access Report: Biosimilars in the United States

Patient Access Report: Biosimilars in the U.S.

Biologics are medicines extracted from a variety of natural sources—human, animal or microorganism—and include a wide range of products such... Read more »

2017 Generic Drug Access and Savings in the U.S. Report

This annual report is produced by the IQVIA, the standard-bearer for measuring data, pharmaceutical use and spending in the United... Read more »

Recent Tweets